Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study.
Journal
HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
11
07
2019
accepted:
19
09
2019
entrez:
25
1
2020
pubmed:
25
1
2020
medline:
25
1
2020
Statut:
epublish
Résumé
Chemotherapy associated osteoporosis is a severe problem in patients with malignant diseases as it increases the risk for fractures and deteriorates quality of life. There are very limited data in the literature for the effect of chemotherapy on bone metabolism of adult patients with Non-Hodgkin Lymphoma (NHL). We prospectively evaluated bone remodeling pre- and post-chemotherapy in 61 patients with newly diagnosed NHL. First-line chemotherapy resulted in high bone turnover, which led to increased bone loss and reduced bone mineral density (BMD) of lumbar spine (L1-L4) and femur neck (FN). The reduction of L1-L4 and FN BMD post-chemo was more profound in males and in older patients (>55 years). Patients who received 8 cycles of chemotherapy had a greater reduction of L1-L4 and FN BMD as compared to 6 cycles. The administration of chemotherapy also resulted in a dramatic increase of bone resorption markers (CTX and TRACP-5b), bone formation markers, (bALP and Osteocalcin) and of osteoblast regulator Dickkopf-1. During study period, one patient had a pathological fracture in his right FN.
Identifiants
pubmed: 31976477
doi: 10.1097/HS9.0000000000000303
pii: HEMASPHERE-2019-0142
pmc: PMC6924549
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e303Informations de copyright
Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Ann Oncol. 2014 Feb;25(2):481-6
pubmed: 24401926
Rheumatology (Oxford). 2000 Dec;39(12):1383-9
pubmed: 11136882
J Clin Oncol. 1996 May;14(5):1718-29
pubmed: 8622093
Support Care Cancer. 2018 Sep;26(9):3013-3020
pubmed: 29549514
Ann Oncol. 2014 Apr;25(4):913-914
pubmed: 24667725
J Clin Invest. 1989 Jun;83(6):1930-5
pubmed: 2524504
Blood. 2009 Jan 15;113(3):517-25
pubmed: 18687985
J Clin Endocrinol Metab. 2001 Jun;86(6):2787-91
pubmed: 11397888
J Bone Miner Res. 2000 Jun;15(6):993-1000
pubmed: 10841167
J Clin Oncol. 2000 Apr;18(7):1570-93
pubmed: 10735906
Anticancer Res. 2003 Mar-Apr;23(2A):1027-9
pubmed: 12820342
Hemasphere. 2019 Sep 24;3(6):e303
pubmed: 31976477
J Bone Miner Metab. 2009;27(5):605-12
pubmed: 19381754
Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):99-105
pubmed: 23276888
Arch Intern Med. 2008 Mar 10;168(5):469-76
pubmed: 18332290
Br J Clin Pract Suppl. 1996 Sep;87:5-7; discussion 13-4
pubmed: 8995010
Leuk Lymphoma. 2007 Aug;48(8):1514-21
pubmed: 17701582
Bone Miner. 1986 Feb;1(1):27-39
pubmed: 3508715
Calcif Tissue Int. 2008 Apr;82(4):278-87
pubmed: 18421493
Lancet. 1983 Jan 22;1(8317):146-9
pubmed: 6130197
J Intern Med. 1998 Oct;244(4):271-92
pubmed: 9797491
Bone. 2008 Mar;42(3):467-75
pubmed: 18180210
RMD Open. 2015 Apr 08;1(1):e000014
pubmed: 26509049
Br J Cancer. 2009 Feb 10;100(3):455-63
pubmed: 19156143
Leukemia. 2005 Nov;19(11):1969-76
pubmed: 16079895
J Clin Endocrinol Metab. 1999 Sep;84(9):3174-81
pubmed: 10487683
Rheumatol Int. 2009 Oct;29(12):1403-9
pubmed: 19219607
J Clin Endocrinol Metab. 1996 Oct;81(10):3441-7
pubmed: 8855781
Am J Med. 2004 Apr 15;116(8):524-8
pubmed: 15063813
Leuk Lymphoma. 2017 May;58(5):1105-1113
pubmed: 27736260
Clin Epidemiol. 2013;5:97-103
pubmed: 23576882
Acta Oncol. 2017 Apr;56(4):590-598
pubmed: 28077016